Akers Biosciences Inc. reported preliminary consolidated earnings results for the year ended December 31, 2011. For the period, the company reported total revenue of $1,785,068 against $3,053,281 for the same period a year ago. Loss from operations was $3,852,830 compared to $1,132,593 for the same period a year ago. Loss before income taxes was $3,882,168 compared to $1,203,296 for the same period a year ago. Net loss was $3,584,278 compared to $919,883 for the same period a year ago. Basic & diluted loss per share was $0.02 compared to $0.01 for the same period a year ago. Net cash used in operating activities was $2,261,762 compared to net cash used in operating activities of $1,729,100 for the same period a year ago. Purchases of property, plant and equipment was $57,179 compared to $256,285 for the same period a year ago. Adjusted loss before tax was $3.58 million compared with $920,000 a year ago. Loss before interest, depreciation, taxes & amortization was $3.3 million against $649,000 a year ago. The company provided earnings guidance for the third quarter fiscal 2012. For the quarter, the company expected measurable results to accrue beginning of 2012.